Osilodrostat 1mg
( DrugBank: Osilodrostat / KEGG DRUG: Osilodrostat )
1 disease
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
75 | Cushing disease | 25 |
75. Cushing disease
Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127
Showing 1 to 10 of 25 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2018-001522-25-IT (EUCTR) | 20/01/202020200120 | 28/04/202020200428 | A study of osilodrostat in children and adolescents with Cushing's disease | A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmac ... | Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disea ... | Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 5mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 10mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osi ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Phase 2 | United States;Slovenia;Spain;Belgium;Bulgaria;United Kingdom;Italy | ||
2 | EUCTR2017-002840-34-NL (EUCTR) | 14/11/201920191114 | 31/07/201920190731 | Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat study Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have c ... | An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous ... | Cushing's syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Cushing's syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndr ... | Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 5mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 10mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osi ... | Recordati AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Phase 2 | Portugal;United States;Spain;Costa Rica;Thailand;Turkey;Austria;Russian Federation;Italy;India;France;Canada;Argentina;Poland;Belgium;Brazil;Bulgaria;Germany;Netherlands;China;Japan;Korea, Republic of Portugal;United States;Spain;Costa Rica;Thailand;Turkey;Austria;Russian Federation;Italy;India;Franc ... | ||
3 | EUCTR2018-001522-25-ES (EUCTR) | 02/10/201920191002 | 26/07/201920190726 | A study of osilodrostat in children and adolescents with Cushing's disease | A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmac ... | Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disea ... | Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 5mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 10mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osi ... | Novartis Farmacéutica, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 2 | United States;Slovenia;Belgium;Spain;Bulgaria;Italy;United Kingdom | ||
4 | EUCTR2017-002840-34-FR (EUCTR) | 08/07/201920190708 | 14/06/201820180614 | Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat study Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have c ... | An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous ... | Cushing's syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Cushing's syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndr ... | Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 5mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 10mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osi ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Phase 2 | United States;Portugal;Greece;Thailand;Spain;Costa Rica;Russian Federation;Colombia;Switzerland;Italy;India;France;Netherlands;China;Korea, Republic of;Turkey;Austria;United Kingdom;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Japan United States;Portugal;Greece;Thailand;Spain;Costa Rica;Russian Federation;Colombia;Switzerland;Ital ... | ||
5 | EUCTR2018-001522-25-BG (EUCTR) | 04/07/201920190704 | 26/03/201920190326 | A study of osilodrostat in children and adolescents with Cushing's disease | A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmac ... | Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disea ... | Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 5mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 10mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osi ... | Recordati AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Phase 2 | United States;Slovenia;Spain;Belgium;Bulgaria;United Kingdom;Italy | ||
6 | EUCTR2017-002840-34-BG (EUCTR) | 18/06/201920190618 | 07/09/201820180907 | Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat study Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have c ... | An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous ... | Cushing's syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Cushing's syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndr ... | Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 5mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 10mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osi ... | Recordati AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Phase 2 | United States;Portugal;Greece;Thailand;Costa Rica;Spain;Russian Federation;Colombia;Italy;Switzerland;India;France;Netherlands;China;Korea, Republic of;Turkey;Austria;United Kingdom;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Japan United States;Portugal;Greece;Thailand;Costa Rica;Spain;Russian Federation;Colombia;Italy;Switzerlan ... | ||
7 | EUCTR2018-001522-25-BE (EUCTR) | 05/06/201920190605 | 30/04/201920190430 | A study of osilodrostat in children and adolescents with Cushing's disease | A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmac ... | Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disea ... | Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 5mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 10mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osi ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Phase 2 | United States;Slovenia;Spain;Belgium;Bulgaria;United Kingdom;Italy | ||
8 | EUCTR2018-001522-25-SI (EUCTR) | 10/05/201920190510 | 16/10/201820181016 | A study of osilodrostat in children and adolescents with Cushing's disease | A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmac ... | Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disea ... | Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 5mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 10mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osi ... | Recordati AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Phase 2 | United States;Slovenia;Spain;Belgium;Bulgaria;United Kingdom;Italy | ||
9 | EUCTR2018-001522-25-GB (EUCTR) | 19/03/201920190319 | 27/09/201820180927 | A study of osilodrostat in children and adolescents with Cushing's disease | A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmac ... | Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Cushing's disease MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disea ... | Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 5mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 10mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: OSILODROSTAT Product Name: osi ... | Recordati AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Phase 2 | United States;Slovenia;Spain;Belgium;Bulgaria;Italy;United Kingdom | ||
10 | EUCTR2017-002840-34-BE (EUCTR) | 07/02/201920190207 | 16/11/201820181116 | Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat study Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have c ... | An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous ... | Cushing's syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Cushing's syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndr ... | Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 5mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 10mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osilodrostat 1mg Product Code: LCI699 INN or Proposed INN: osilodrostat Product Name: osi ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Phase 2 | United States;Portugal;Greece;Thailand;Spain;Costa Rica;Russian Federation;Colombia;Switzerland;Italy;India;France;Netherlands;China;Korea, Republic of;Turkey;Austria;United Kingdom;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Japan United States;Portugal;Greece;Thailand;Spain;Costa Rica;Russian Federation;Colombia;Switzerland;Ital ... |